Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cancer Research|December 21, 2017
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple MechanismsMinah Kim, Maximilian Nitschké, Barbara Sennino, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2015
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal CancerSe Hoon Park, Caroline J Breitbach, Jeeyun Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2014
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patientsTimothy P Cripe, Minhtran C Ngo, James I Geller, et al.
Cancer Research|October 24, 2012
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cellsLee-Hwa Tai, Christiano Tanese de Souza, Simon Bélanger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Targeting tumor vasculature with an oncolytic virusCaroline J Breitbach, Naomi S De Silva, Theresa J Falls, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyJeong Heo, Caroline J Breitbach, Anne Moon, et al.
Cancer Research|February 9, 2013
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humansCaroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersKelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLaura Evgin, Sergio A Acuna, Christiano Tanese de Souza, et al.
Pageof 4